Biopharmaceutical company BioSpecifics Technologies Corp (NASDAQ:BSTC) stated on Friday its net income of USD2.7m (USD0.38 per basic share, USD0.37 per share on a fully diluted basis) for the third quarter ended 30 September 2017.
This marks a drop in earnings when compared with net income of USD3.1m (USD0.43 per basic share, USD0.42 per share on a fully diluted basis) for the same period in 2016.
Total revenues of USD6.5m were collected for the third quarter ended 30 September 2017, down over total revenue of USD6.9m for the same period in 2016.
Research and development expenses of USD0.4m were recorded for the third quarter ended 30 September 2017, a rise from R&D of USD0.3m for the same period in 2016.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development